Study results are expected for a pair of closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs. In early May, executives at Amgen gave a rosy review of their experimental drug for obesity, telling investors they were confident the medicine could soon move into late-stage testing. The bullish comments were enough to swell the company’s market value, already among the industry’s largest, by nearly $20 billion.

10 clinical trials to watch in the second half of 2024 | BioPharma Dive